Takeda Pharmaceuticals of Osaka, Japan won FDA approval yesterday to market a new uricosuric agent in the US market for the treatment of gout. The drug will be marketed as Uloric (febuxostat) and will be marketed as an alternative to allopurinal.
I’ve prescribed allopurinal for years with no ill effects. My question is this; what are the benefits of Uloric? As a new patented medication, Uloric is sure to cost much more than generic allopurinal. I think the jury is still out.
Jeffrey A. Oster, DPM
Medical Director
Myfootshop.com
